
Kaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101
Represents significant milestone in the development of KAD101, a novel biologic prolactin receptor antagonist, being initially developed for the treatment of platinum resistant ovarian cancer (PROC) with expansion opportunities into endometrial, uterine …